Market Place
Sourcing Support
Immuneering Touts 64% Survival, Fueling Race With Revolution
08 Jan 2026 //
FIERCE BIOTECH
Immuneering Announces 12-Month OS Data From Atebimetinib Trial
23 Dec 2025 //
GLOBENEWSWIRE
Immuneering Aligns with FDA, EMA on Atebimetinib Phase 3 Trial
17 Dec 2025 //
GLOBENEWSWIRE
Immuneering To Present Q3 2025 Financials & New Clinical Cases
04 Nov 2025 //
GLOBENEWSWIRE
Immuneering To Share OS Data From Ph 2a Pancreatic Cancer Trial
26 Sep 2025 //
GLOBENEWSWIRE
Immuneering Boosts Pancreatic Cancer Survival By Nearly 2x
25 Sep 2025 //
BIOSPACE
Immuneering`s Ph 2a Update on Atebimetinib + mGnP for Cancer
10 Sep 2025 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.